Результаты поиска

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.

The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months. The study was carried out on 234 patients who received THAL for relapsed/refractory myeloma. Out of the 234 patients, 129 patients (55.1%) responded to THAL with a mean response duration of 11.9 months (ranging from 1 to 48) and an overall survival rate of 20.3 months (ranging 1-55 months). In 64 patients (27.4% of the whole group), the response to THA

Совпадение в полном тексте источника
… Br J Haematol 120: 18–26 Cheng D, Kini AR, Rodriguez J, Burt R, Peterson LC, Tray nor AE (1999) Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. …

2022 NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF HYPERTENSION (SIIA)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The roles of osteoprotegerin in cancer, far beyond a bone player.

Osteoprotegerin (OPG), also known as tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a member of the tumor necrosis factor (TNF) receptor superfamily. Characterized by its ability to bind to receptor activator of nuclear factor kappa B ligand (RANKL), OPG is critically involved in bone remodeling. Emerging evidence implies that OPG is far beyond a bone-specific modulator, and is involved in multiple physiological and pathological processes, such as immunoregulation, vascular function, and fibrosis. Notably, numerous preclinical and clinical studies have been conducted to

miR‑140‑5p inhibits the proliferation of multiple myeloma cells by targeting VEGFA.

MicroRNA (miR)‑140‑5p is associated with the growth and metastasis of various tumor cell types, yet its role in multiple myeloma (MM) remains unclear. Therefore, the present study aimed to investigate the regulatory effect of miR‑140‑5p on MM. Reverse transcription‑quantitative PCR analysis demonstrated that miR‑140‑5p was downregulated in MM cell lines, particularly in U266 and RPMI 8226 cells. A Cell Counting Kit‑8, wound healing and Transwell assays, as well as flow cytometry indicated that a miR‑140‑5p mimic could suppress cell viability, migration and invasion. In addition, the mimic prom

A review of mitochondrial dysfunction in diabetic sarcopenia: Mechanisms, diagnosis, and treatment approaches.

Diabetic sarcopenia is a common complication of diabetes, substantially impacting patients' quality of life and prognosis. Its pathogenesis is closely related to energy metabolism, with mitochondria-often referred to as the cellular "powerhouse"-playing a central role in this process. This review focuses on the role of mitochondrial dysfunction in diabetic sarcopenia, emphasizing mechanisms such as energy metabolism imbalance, oxidative stress-induced damage, and abnormalities in mitochondrial biogenesis and dynamics. Additionally, we discussed current research on diagnostic and therapeutic st

Распространение остеопороза в хронических заболеваниях: зонтичный обзор 283 наблюдения, полученные в ходе 13 систематического обзора.

ВВЕДЕНИЕ: Остеопороз - это болезнь, характеризующаяся снижением плотности минералов кости и ухудшением микроархитектуры кости, что повышает риск разрушения. В контексте различных хронических патологий это состояние может привести к еще более высокому уровню заболеваемости, смертности и бремени здравоохранения. ЦЕЛЬ: Обобщать и сопоставлять имеющиеся данные, полученные в ходе систематических обзоров распространения остеопороза среди различных хронических заболеваний. МЕТОДОЛОГИЯ: В соответствии с руководящими принципами ПРИСМА был проведен зонтичный обзор с уделением особого внимания систематич

37th International Symposium on Intensive Care and Emergency Medicine (part 1 of 3) : Brussels, Belgium. 21–24 March 2017

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Derivation and Characterization of Endothelial Cells from Porcine Induced Pluripotent Stem Cells.

Although the study on the regulatory mechanism of endothelial differentiation from the perspective of development provides references for endothelial cell (EC) derivation from pluripotent stem cells, incomplete reprogramming and donor-specific epigenetic memory are still thought to be the obstacles of iPSCs for clinical application. Thus, it is necessary to establish a stable iPSC-EC induction system and investigate the regulatory mechanism of endothelial differentiation. Based on a single-layer culture system, we successfully obtained ECs from porcine iPSCs (piPSCs). In vitro, the derived piP

Keyword Index for Volume 110

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ZD6474--clinical experience to date.

ZD6474 selectively targets two key pathways in tumour growth by inhibiting vascular endothelial growth factor (VEGF)-dependent tumour angiogenesis and epidermal growth factor (EGF)-dependent tumour cell proliferation and survival. Phase I clinical evaluation has shown ZD6474 to be generally well tolerated, with a pharmacokinetic profile appropriate for once-daily oral dosing. Phase II evaluation of ZD6474 at doses of 100-300 mg is ongoing in a range of patient types in single and combination regimens. These include three randomised studies of patients with non-small-cell lung cancer. In one of

Совпадение в полном тексте источника
… In addition, a correlation between outcome or response and tumour VEGFR expression and microvascular density will be assessed. …

A Rare and Fatal Case of Hemophagocytic Lymphohistiocytosis Associated with Sarcoidosis.

BACKGROUND Sarcoidosis is a systemic inflammatory disorder characterized by a classic pathologic feature of non-caseating granulomas involving any organ system. Hemophagocytic lymphohistiocytosis (HLH) is a catastrophic cytokine surge characterized by dysregulation of the macrophage response, which can be rapidly fatal. Recognition of HLH has been increasing over the past decade. HLH can present with features of sepsis that can make the diagnosis challenging and requires high clinical suspicion. CASE REPORT We report a case of a 48-year-old African American male with a past medical history of

Роль Neuroptide Y в зубной касти: уравновешивание нейрогенного воспаления и модуляции боли.

ВЕЩЕСТВО: Стоматологическая целлюлоза представляет собой густонаселенную, низкосопоставимую ткань, в которой нейронное воспаление может быстро перерасти в отеку, поднимает внутрипульсовое давление, микроваскулярный компромисс и боль. В то время как пептид вещества P (SP) и кальцитонин (CGRP) являются хорошо зарекомендовавшими себя движущими силами вазодиляции целлюлозы, внутренний контррегулятивный механизм Neuroopepide Y (NPY) остается относительно недостаточно изученным.ЦЕЛИ: Критически синтезировать текущие данные по NPY в области стоматологической биологии целлюлозы с уделением особого вни

Chimeric antigen receptor-based cell therapy for treating urological tumors.

Urological tumors represent a significant global health challenge, with conventional therapies often proving insufficient to control disease progression. Recent breakthroughs in cellular immunotherapy, particularly in chimeric antigen receptor (CAR)-T cell, CAR-natural killer cell, and CAR-macrophage therapies, have demonstrated remarkable potential for treating these malignancies. Ongoing research is actively refining CAR-based strategies to enhance their precision in targeting tumor-associated antigens. This review comprehensively summarizes the applications of CAR cell therapy in the follow

The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.

Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed. During the last five years, the landscape of the pharmacotherapy of SCD has changed dramatically. Currently, 54 drugs have been used or under consideration to use for the treatment of SCD. These fall into 3 categories: the first category includes the four drugs (Hydroxyurea, L-Glutamine, Crizanlizumab tmca and Voxelotor) that have been approved by the United States Food and Drug Administration (FDA) based on suc

Emerging disease-modifying therapies for sickle cell disease.

Sickle cell disease afflicts millions of people worldwide and approximately 100,000 Americans. Complications are myriad and arise as a result of complex pathological pathways 'downstream' to a point mutation in DNA, and include red blood cell membrane damage, inflammation, chronic hemolytic anemia with episodic vaso-occlusion, ischemia and pain, and ultimately risk of cumulative organ damage with reduced lifespan of affected individuals. The National Heart, Lung, and Blood Institute's 2014 evidence-based guideline for sickle cell disease management states that additional research is needed bef

Resveratrol and Curcumin for Chagas Disease Treatment-A Systematic Review.

Chagas disease (CD) is a neglected protozoan infection caused by Trypanosoma cruzi, which affects about 7 million people worldwide. There are two available drugs in therapeutics, however, they lack effectiveness for the chronic stage-characterized mainly by cardiac (i.e., cardiomyopathy) and digestive manifestations (i.e., megaesophagus, megacolon). Due to the involvement of the immuno-inflammatory pathways in the disease's progress, compounds exhibiting antioxidant and anti-inflammatory activity seem to be effective for controlling some clinical manifestations, mainly in the chronic phase. Re

The Potential of Chronotherapy and Nanotherapy-Based Strategies for Glioblastoma Treatment.

Glioblastoma is the most common and aggressive brain tumour in adults, and despite ongoing efforts, effective treatment remains limited. Standard therapies often face challenges because of the tumour's specific biology, its aggressive nature, and the presence of certain physiological barriers in the brain that impede chemotherapeutics from reaching their target. Emerging research in circadian biology highlights the role of the internal circadian clock in tumour progression and treatment response. Evidence suggests that aligning therapy to patients' chronotypes could potentially improve treatme

Совпадение в полном тексте источника
… In addition, elevated levels of BMAL1 mRNA expression in grade III glioblastoma have been demonstrated to be associated with diminished survival periods, oedema severity, and an increased microvascular density [ 37 ]. …

Keyword Index for Volume 95

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Комплексный номер копий с высоким разрешением и гистомолекулярный анализ диффузной глиомы в масштабах полушария, H3 G34-mutant обнаруживает общие аномалии TP53.

Диффузная глиома в масштабах полушария, Н3 G34-mutant (В тыс.DHG-H3 G34 характеризуется главным образом молекулярным профилированием метилирования и исследованиями последовательности. Мы описываем комплексную гистомолекулярную оценку, включая профили копий с высоким разрешением серии 60 DHG-H3 G34 для дальнейшего понимания спектра генетических изменений, связанных с этим типом опухолей. Случаи были подвергнуты клиническому тестированию с использованием: 187-gene мутация и синтез были нацелены на нейроонтологию следующего поколения (n = 60) и онкосканского хромосомного микроаррара (n = 26) одно

Эффективность лазерной фотореактивной модуляции в управлении тригеминальной невралгией: систематический обзор и мета-анализ.

Настоящее систематическое обзорное исследование посвящено оценке эффективности лазерной фотобиомодуляции (ПБМ) в снижении боли у пациентов с тригеминальной невралгией и постгерпетической невралгией. Случайные контролируемые клинические испытания были идентифицированы через поиск в следующих базах данных: PubMed, Web of Science, LILACS, EMBASE, Scopus и Cochrane Library. Нет исследований, вовлекающих пациентов с постгерпетической невралгией, которые соответствовали критериям включения и были поэтому исключены. Включено девять исследований, включающих итого 387 пациентов с диагнозом тригеминальн